Bioatla 

Yahoo Finance • 5 months ago

BioAtla, Inc. (BCAB): Among Michael Burry’s Top 10 Stock Picks Heading Into 2025

We recently compiled a list of the Michael Burry's Top 10 Stock Picks Heading into 2025.In this article, we are going to take a look at where BioAtla, Inc. (NASDAQ:BCAB) stands against Michael Burry's other stock picks. Established in May... Full story

Yahoo Finance • last year

After losing 78% in the past year, BioAtla, Inc. (NASDAQ:BCAB) institutional owners must be relieved by the recent gain

Key Insights Significantly high institutional ownership implies BioAtla's stock price is sensitive to their trading actions A total of 11 investors have a majority stake in the company with 52% ownership Analyst forecasts along with owner... Full story

Yahoo Finance • last year

BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023

BioAtla, Inc. SAN DIEGO, Dec. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatme... Full story

Yahoo Finance • last year

BioAtla to Participate in the JMP Securities Hematology and Oncology Summit

SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid t... Full story

Yahoo Finance • last year

BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC

SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid t... Full story

Yahoo Finance • last year

BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress

Observed additional clinical responses and FDA feedback supports path forward for CAB-AXL-ADC (BA3011) non-small cell lung cancer (NSCLC) registrational study; detailed interim Phase 2 data to be presented at upcoming IASLC conference in e... Full story

Yahoo Finance • last year

BioAtla to Participate in the Jefferies London Healthcare Conference

SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid t... Full story

Yahoo Finance • last year

BioAtla’s Jay M. Short, Ph.D., Selected for The Explorers Club Lowell Thomas Award

SAN DIEGO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid t... Full story

Yahoo Finance • last year

BioAtla Provides Guidance on Near-Term Milestones and Plans to Announce Third Quarter 2023 Financial Results and Business Update on November 7, 2023

Submitted abstract on CAB-AXL-ADC, BA3011, in non-small cell lung cancer (NSCLC) to the IASLC 2023 North America Conference on Lung Cancer; KOL event planned for December 4, 2023, following conclusion of the IASLC conference R&D day planne... Full story

Yahoo Finance • 2 years ago

BioAtla to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid... Full story

Yahoo Finance • 2 years ago

BioAtla Added to Membership of U.S. Small-Cap Russell 2000® Index

SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid t... Full story

Yahoo Finance • 2 years ago

BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023

SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tu... Full story

Yahoo Finance • 2 years ago

BioAtla Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress

- Cleared dose-limiting toxicity (DLT) observation period with more frequent, dose-intensive regimen of CAB-AXL BA3011; anticipated leiomyosarcoma (LMS) cohort readout in 2H23 - Initiated the potentially registrational Phase 2, part 2 BA3... Full story

Yahoo Finance • 2 years ago

BioAtla to Announce Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Highlights

SAN DIEGO, March 16, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid... Full story

Yahoo Finance • 2 years ago

BioAtla Announces Change in Executive Leadership

SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid t... Full story

Yahoo Finance • 2 years ago

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of Advanced Adenocarcinoma

Following the IND clearance, the Company is advancing into a Phase 1 clinical study Potentially addressing most common subtypes of adenocarcinoma including colon, lung, breast, pancreas, and prostate SAN DIEGO, Feb. 23, 2023 (GLOBE NEW... Full story

Yahoo Finance • 2 years ago

BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones

Mecbotamab vedotin (BA3011) Phase 2 part 1 interim results in PD-1 failure NSCLC continues to show strong antitumor activity in a highly refractory population with additional patients enrolled BA3011 Undifferentiated Pleomorphic Sarcoma (... Full story

Yahoo Finance • 2 years ago

BioAtla to Participate in the 41st Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid t... Full story

Yahoo Finance • 2 years ago

BioAtla Announces $65 Million Underwritten Offering of its Common Stock

SAN DIEGO, Nov. 04, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid t... Full story

Yahoo Finance • 2 years ago

BioAtla Reports Third Quarter 2022 Financial Results and Highlights Recent Progress

Mecbotamab vedotin (BA3011) Phase 2 part 1 interim results in NSCLC continue to show antitumor activity with additional patients enrolled BA3011 Undifferentiated Pleomorphic Sarcoma (UPS) enrollment in Phase 2 part 2 of study anticipated t... Full story